SILO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to lack of positive earnings.
- P/B ratio is relatively low at 1.09
- Price/Sales ratio of 116.19 is astronomically high
- No earnings to support a P/E valuation
Growth metrics are stagnant or declining.
- Recent short-term price recovery
- 0% Revenue growth
- Negative EPS growth (-71.4% Q/Q)
Historical performance shows consistent value erosion.
- 5Y Change: -96%
- 1Y Change: -52.1%
Altman Z-Score not provided, but F-Score indicates maximum weakness.
- High Current Ratio (11.36) provides a liquidity buffer
- Piotroski F-Score 0/9
- ROE of -74.57%
Dividend Strength 0/100.
- No dividend history
- No capacity to pay dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SILO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SILO
Silo Pharma, Inc.
Primary
|
-96.0% | -78.0% | -52.1% | -8.0% | +60.9% | +16.8% |
|
NOTV
Inotiv, Inc.
Peer
|
-98.8% | -95.0% | -84.2% | -82.6% | -31.9% | -2.0% |
|
GELS
Gelteq Limited
Peer
|
-73.9% | -73.9% | -14.8% | -43.5% | +3.7% | +13.2% |
|
IMRN
Immuron Limited
Peer
|
-85.9% | -59.6% | -51.9% | -61.7% | -3.3% | -1.0% |
|
EVGN
Evogene Ltd.
Peer
|
-98.3% | -86.8% | -23.5% | -45.0% | +5.7% | -0.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SILO
Silo Pharma, Inc.
|
BEARISH | $8.38M | - | -74.6% | -% | $0.52 | |
|
NOTV
Inotiv, Inc.
|
BEARISH | $8.43M | - | -49.8% | -13.5% | $0.24 | Compare |
|
GELS
Gelteq Limited
|
BEARISH | $8.23M | - | -43.0% | -% | $0.77 | Compare |
|
IMRN
Immuron Limited
|
BEARISH | $8.1M | - | -39.7% | -62.1% | $0.79 | Compare |
|
EVGN
Evogene Ltd.
|
BEARISH | $7.95M | - | -100.7% | -220.2% | $0.8 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | WEISBLUM ERIC | Chief Executive Officer | Purchase | 5,000 | $2,075 |
| 2025-11-21 | WEISBLUM ERIC | Chief Executive Officer | Purchase | 2,000 | $735 |
| 2025-11-19 | WEISBLUM ERIC | Chief Executive Officer | Purchase | 12,000 | $4,847 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
SILO filed its 10-K annual report on March 27, 2026, which includes detailed disclosures on its business operations, risk factors, and financial condition. While specific financial metrics were not provided in the excerpts, the filing contains the company's comprehensive management discussion and analysis of its results of operations.
SILO has secured exclusive global rights to develop and commercialize SPC-14 for the treatment of Alzheimer’s and depression disorders through a license agreement with Columbia University. The company reports that SPC-14 has shown efficacy in attenuating anxiety and learned helplessness; however, no specific financial metrics or detailed risk factors were provided in the excerpt.
Past News Coverage
Recent headlines mentioning SILO from our newsroom.